Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Recursion gets FDA approval to begin phase 1 trials of AI-discovered ******* treatment

Source: Recursion Pharmaceuticals

AI ***** pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone.

Recursion was able to use its artificial intelligence-enabled ***** discovery platform to identify an area of biology to target for the treatment of solid tumors and lymphoma, match it with a ***** candidate and move all the way to gaining regulatory approval to begin studies in less than 18 months.

“We think that’s a really exciting proof point, not only for us as a company, but I think for the techbio industry as well,” said CEO and co-founder Chris Gibson, in an interview with CNBC.

The Food and ***** Administration cleared the investigational new ***** application for a phase 1/2 clinical trial of an experimental ***** candidate known as REC-1245. The company said the potential market for this treatment could be more than 100,000 patients in the U.S. and ********* Union.

The trial will evaluate the safety and tolerability of REC-1245 and will begin in the fourth quarter of this year. The phase 1 data from the dose-escalation portion of the study could be completed by the end of next year, the company has said.

The ***** will target RBM39, which Recursion said appears functionally similar to a well-known but hard to target marker known as CDK12 to treat advanced HR-proficient cancers such as ovarian, prostate, ******* and pancreatic cancers.

“I think what’s really exciting about this particular program of Recursion is that this small molecule and novel target came out from essentially a

This is the hidden content, please

• Sign In
• or
• Sign Up

-search equivalent, from this giant map of biology that we’ve already built,” Gibson said, referring to the massive datasets that Recursion has created over the past 11 years.

“This is the first program that’s come of that,” he continued. “It’s the first program that really is leveraging many of these new tools that we’ve built in one unit.”

There is much hope that artificial intelligence will be able to significantly speed up ***** discovery and make it less costly by eliminating some of the time-consuming trial-and-error as ***** candidates are screened and selected. But investors have been wanting to see that the reality can live up to the hype.

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Recursion shares year to date

Recursion, which counts Nvidia among its investors, has seen its shares fall 38% in 2024. But the stock is still more than 60% below a 52-week high it hit in late February.

The company is planning to merge with fellow AI-***** discovery company Exscientia, which will allow it to harness even more data. The deal is expected to close early next year.

The majority of analysts rate Recursion shares a hold, but two analysts do have a buy rating on the stock, according to FactSet. The average analyst price target of $10.14, implies a 64% return.

This is the hidden content, please

• Sign In
• or
• Sign Up

#Recursion #FDA #approval #phase #trials #AIdiscovered #******* #treatment

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up